Growth hormone administration improves nonalcoholic fatty liver disease in overweight/obesity: a randomized trial.

Laura E DichtelKathleen E CoreyMelanie S HainesMark L ChicoteHang LeeAllison KimballCaitlin CollingTracey G SimonMichelle T LongJad HusseiniMiriam A BredellaKaren K Miller

Published in: The Journal of clinical endocrinology and metabolism (2023)

GH administration reduces hepatic steatosis in adults with overweight/obesity and NAFLD without worsening glycemic measures. The GH/IGF-1 axis may offer targetable therapeutic options for NAFLD.

Keyphrases

growth hormone
weight loss
weight gain
type diabetes
insulin resistance
metabolic syndrome
high fat diet induced
body mass index
physical activity
glycemic control